BJMO - volume 6, issue 4, september 2012
T. Feys MBA, MSc
EORTC 90101 CREATE assesses the antitumour activity and safety of crizotinib across predefined tumour types in patients whose tumours are possibly harbouring specific alterations in ALK and/or MET. (BELG J MED ONCOL 2012;6:129–131)
Read more
BJMO - volume 6, issue 3, june 2012
D. Verhoeven MD, PhD, T. Feys MBA, MSc
From the 21st till the 24th of March, Vienna formed the spectacular background for the 8th European Breast Cancer Conference (EBCC). The EBCC was jointly organised by the EORTC, EUSOMA and EUROPA DONNA and welcomed over 3500 participants. This report does not pretend to summarise the entire meeting but aims at discussing the most important take-home messages from the congress. (Belg J Med Oncol 2011;6:106–108)
Read more
BJMO - volume 6, issue 2, april 2012
T. Feys MBA, MSc, J. De Grève MD, PhD
From the 6th – 10th of December, San Antonio, TX was again transformed into the world’s capital in the fight against breast cancer. The Cancer Therapy & Research Center (CTRC) and the American Association for Cancer Research (AACR) were the joint organisers of this 34th edition of the San Antonio Breast Cancer Symposium. This year’s meeting attracted nearly 8,000 participants from over 90 countries and again proved to be the number 1 breast cancer meeting in the world. This report does not aim to summarise the entire meeting but aims at discussing the highlights of the meeting. (BELG J MED ONCOL 2011;6:73–76)
Read more
Top
